Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

Inclusion Criteria: * clinical history consistent with grass pollen-induced allergic rhinoconjunctivitis. * Use of symptomatic treatment of grass pollen-induced allergic rhinoconjunctivitis. * Positive skin prick test response (wheal diameter ≥3 mm) to Phleum pratense. * If asthma, daily use of Inhaled corticosteroid (ICS) should be ≤400 microgram budesonide or equivalent * Moderate or higher level of Phleum pratense specific IgE (Immunoglobulin E) (defined as ≥IgE Class 2; or ≥0.70 Kilo Units/liter (kU/L)) Exclusion Criteria: * Reduced lung function (defined as FEV1 \< 70% (FEV1=Forced Expiratory Volume in 1 second) of predicted value after adequate pharmacologic treatment) measured at Visit 1 and Visit 2 * Clinical history of uncontrolled asthma within 3 months prior to the screening visit